Pacgen Initiates Phase IIb Clinical Trial for Treatment of Oral Candidiasis
Posted on: Tuesday, 20 November 2007, 15:00 CST
Pacgen Biopharmaceuticals has initiated a Phase IIb dose-ranging clinical trial for an optimized formulation of PAC-113, a novel treatment for oral candidiasis infection.
This study will be a randomized, examiner-blinded, parallel design trial comparing three different doses of PAC-113 to Nystatin, a topical mouth rinse treatment for oral candidiasis.
The study is expected to be completed in the second quarter of 2008, and will enroll approximately 200 seropositive HIV patients with oral candidiasis in a number of US and South African centers.
Final results from the previous Phase I/II trial showed per protocol PAC-113 treated group had a complete clinical cure rate of 44%, comparable to the per protocol Nystatin treated group at 40%. Results confirm that PAC-113 was generally safe, well tolerated, and active in the treatment of oral candidiasis infection.
Pacgen believes the optimized formulation of PAC-113 will show superior clinical efficacy as compared both to the prior PAC-113 formulation and to Nystatin.
PAC-113 is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in human saliva.
Source: Datamonitor
Related Articles
- Pacgen Announces Positive Results From Phase IIb Dose-Ranging Trial of PAC-113
- Collegium Presents Positive Clinical Data for Oral Oxycodone Formulation
- Pacgen Initiates a Phase IIb Clinical Trial For PAC-113
- Pacgen Presents Research Data at ACCP on Evaluation of a New Host Derived Synthetic Antifungal Peptide (PAC-113) in the Treatment of Oral Candidiasis
- NovaDel Announces Positive Results From Pharmacokinetic Study of Improved Sumatriptan Oral Spray Formulation
- Emisphere Reports Results of Study Comparing Its Oral Heparin Formulation to Traditional Injectable Heparin
- Oral Solution Formulation of Namenda(R), the Only FDA-Approved Oral Solution for Moderate to Severe Alzheimer's Disease, Now Available
- Oral Candidiasis in Pediatric HIV Patients
- Vertex Pharmaceuticals Announces Advancement to Phase Ib Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C
 |
 |
User Comments (0)
RSS Feeds